Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volanesorsen in Familial Chylomicronemia Syndrome (FCS)
NCT02211209Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in familial chylomicronemia syndrome (FCS) comparing Volanesorsen with Placebo (2 arms). Primary endpoint: Percent Change in Fasting Triglycerides From Baseline to Month 3. Started Dec 2014; status: completed.
02
Drugs
volanesorsen
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT02211209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211209.